The treatment landscape for CLL has changed dramatically in the past 10 years. With three approved BTK inhibitors, and several more on the horizon, choosing which agent to use in the first-line continues to present a challenge to hematologists/oncologists and care teams. As the choice of first-line agent has ramifications for future lines of therapy, hematologists/oncologists need to be able to map out the treatment journey while keeping in mind that therapy resistance or intolerance may arise and that AEs may diminish adherence to therapy. In this Creative Educational Concepts Enduring Webcast, expert faculty will guide learners through the latest clinical data that informs best practices (including sequencing BTKis), the rationale and support for combination therapies, and the need to factor in the needs and preferences of patients.
- Provider:Creative Educational Concepts, Inc.
- Activity Link: https://www.ceconcepts.com/?post_type=activity&p=2356&preview=true
- Start Date: 2023-12-15 06:00:00
- End Date: 2023-12-15 06:00:00
- Credit Details: IPCE Credits: 1.5 hours
AAPA Category 1 Credit™️: 1.5 hours
AMA PRA Category 1 Credit™️: 1.5 hours
Nursing: 1.5 hours
Pharmacy: 1.5 hours - MOC Credit Details: ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 0.0 - Is Kind Support: False Source: Lilly (Any division) - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine